Allogene Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
ALLO$1.06+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the Company’s last fiscal quarter, one of the Company’s directors adopted a written plan for the sale of the Company’s common stock set forth in the table below.
| Type of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position | Action | AdoptionDate | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Common Stock to be Sold | Expiration Date |
| Deborah Messemer, Director | Adoption | August 30, 2024 | X | ― | 61,529 | June 30, 2025 |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.